KANG, Heun Soo,강흔수,KIM, Hye Mi,김혜미,SONG, Ji Eun,송지은,YIN, Yingfu,인잉푸,SHIN, Ji Woong,신지웅,KANG, Hye Won,강혜원,KIM, Yong Hwan,김용환
申请号：
KRKR2018/008239
公开号：
WO2020/017676A1
申请日:
2018.07.20
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
The present invention provides a therapeutic stem cell composition in which a stem cell comprises, in a proportion that is higher or lower than that of a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene, at least one gene selected from the group consisting of ACAN, SOX9, AP2, RUNX2, OCN, ALP, OCT4, SOX2, CXCR4, cMET, PDGFRA, PDGFRB, VEGF-R1, VEGF-R2, CSF-1, IDO2, Sox2, Nanog, cMyc, Klf2, Klf4, Rex1, Esrrb, Neurog1, Neurod1, Nkx2.2, Ascl2, Gfap, S100b, Olig2, Neurog2, T, Nkx2.5, Esrrbb, Klf2, Klf4, cTnT, a-Actin, Mlc2v, and Runx1.La présente invention concerne une composition de cellules souches thérapeutiques dans laquelle une cellule souche comprend, dans une proportion qui est inférieure ou supérieure à celle d'un gène glycéraldéhyde 3-phosphate déshydrogénase (GAPDH), au moins un gène choisi dans le groupe constitué par ACAN, SOX9, AP2, RUNX2, OCN, ALP, OCT4, SOX2, CXCR4, cMET, PDGFRA, PDGFRB, VEGF-R1, VEGF-R2, CSF-1, IDO2, Sox2, Nanog, cMyc, Klf2, Klf4, Rex1, Esrrb, Neurog1, Neurod1, Nkx2.2, Ascl2, Gfap, S100b, Olig2, Neurog2, T, Nkx2.5, Esrrbb, Klf2, Klf4, cTnT, a-actine, Mlc2v, et Runx1.본 발명은 치료용 줄기세포 조성물에 있어서, 상기 줄기세포는 ACAN, SOX9, AP2, RUNX2, OCN, ALP, OCT4, SOX2, CXCR4, cMET, PDGFRA, PDGFRB, VEGF-R1, VEGF-R2, CSF-1, IDO2, Sox2, Nanog, cMyc, Klf2, Klf4, Rex1, Esrrb, Neurog1, Neurod1, Nkx2.2, Ascl2, Gfap, S100b, Olig2, Neurog2, T, Nkx2.5, Esrrbb, Klf2, Klf4, cTnT, a-Actin, Mlc2v, 및 Runx1으로 이루어진 군으로부터 어느 하나 이상의 유전자가 GAPDH(Glyceraldehyde 3-phosphate dehydrogenase) 유전자에 비해 높거나 낮은 비율로 포함하는, 치료용 줄기세포 조성물을 제공하는 것이다.
